Clinical trialsCompany release

Oncolytics reports HPV-16 T-cell expansion with pelareorep in second-line anal cancer study

🇺🇸 Oncolytics Biotech Inc (ONCY) · Wed 04 Nov 2026

Translational data at SITC 2026 show immune-activation rises in most evaluable patients, with HPV-16-specific T-cell expansion in six of 14 and tumour shrinkage in four of those six.

Oncolytics Biotech has presented translational data from its Phase 1/2 study of pelareorep combined with a checkpoint inhibitor in patients with squamous cell anal cancer who have received at least one prior line of therapy. The data were shown at the SITC 2026 Annual Meeting, and the company announced them on 4 November 2026.

According to the company, most evaluable patients had rises of more than two-fold in biomarkers of immune activation after a single treatment cycle.

Six of 14 patients showed expansion of T cells specific to HPV-16. Four of those six also had tumour shrinkage. The summary available does not give further detail on response criteria, dosing, the checkpoint inhibitor used or safety findings, so the strength of the link between T-cell expansion and clinical benefit cannot be judged from it.

Oncolytics said it is seeking partners for development in HPV-driven cancers.

What it means for your team

  • The findings are translational and come from a small Phase 1/2 cohort, so they are hypothesis-generating rather than evidence of efficacy.
  • Teams tracking HPV-driven tumours may note the company's stated interest in partnering, which could signal future development or licensing activity.
  • Fuller data on response rates, safety and the checkpoint inhibitor partner would be needed before any regulatory or market-access assessment.

Company's press release (SEC filing): Oncolytics Biotech Inc ↗

Article written by VigiEye from the official source (Oncolytics Biotech Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →